Caricamento...
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
Treatment with the tyrosine kinase inhibitor imatinib is the standard of care for newly diagnosed patients with chronic myeloid leukemia. In recent years, several second-generation inhibitors – such as dasatinib and nilotinib – have become available: these promise to overcome some of the mutations a...
Salvato in:
| Pubblicato in: | Haematologica |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Ferrata Storti Foundation
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4222479/ https://ncbi.nlm.nih.gov/pubmed/25216683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.085977 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|